SIGA

SIGA Technologies, Inc. (NASDAQ:SIGA) is a commercial-stage pharmaceutical company founded in 1995 and incorporated in New York. The company specializes in developing and commercializing medical countermeasures for biological threats and infectious diseases, with a primary focus on national security and health preparedness markets. SIGA went public in 1997 and has evolved from a research-stage biotech into a profitable commercial enterprise, primarily through its flagship antiviral drug TPOXX, which treats smallpox and related orthopoxvirus infections. The company maintains strong relationships with the U.S. government and has expanded internationally, serving customers across multiple continents while maintaining a debt-free balance sheet with substantial cash reserves.